^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    APIS ESR1 Mutations Kit

    Company:
    APIS Assay Techno
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    8d
    Highly Sensitive ESR1 Mutation Detection with the APIS Kit: Performance and LoD Testing in Varied Wild-Type Backgrounds (AMP 2024)
    The APIS ESR1 Mutations Kit demonstrated high sensitivity and specificity as a qualitative qPCR assay for detecting ESR1 mutations in varying WT backgrounds. Its performance with the SensID ESR1 Reference Set 1% AF cfDNA validated the kit's LoD at ≤1% MAF with external samples. The APIS kit is a valuable tool for assessing ESR1 mutations in both clinical and research settings, offering a more accessible alternative to traditional next-generation sequencing (NGS) and dPCR assays.
    ER (Estrogen receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    TP53 mutation • ER positive • KIT mutation • ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537C
    |
    APIS ESR1 Mutations Kit
    19d
    Evaluating the APIS ESR1 Mutations Kit: Performance and LoD Testing in Varied Wildtype Backgrounds (SABCS 2024)
    No abstract available
    ER (Estrogen receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation • ER mutation • ESR1 mutation
    |
    APIS ESR1 Mutations Kit
    2ms
    APIS announces new collaboration (APIS Press Release)
    "PT Global Bioray Teknologi and APIS Assay Technologies Sign Collaboration to Commercialise the ESR1 Mutations Kit & the Breast Cancer Subtyping Kit..."
    Licensing / partnership
    |
    APIS Breast Cancer Subtyping Kit • APIS ESR1 Mutations Kit
    4ms
    APIS announces new collaboration (APIS Press Release)
    "Shiva Scientific and APIS Assay Technologies Sign Collaboration to Commercialise the APIS ESR1 Mutations Kit..."
    Licensing / partnership
    |
    APIS ESR1 Mutations Kit
    5ms
    Measuring ESR1 mutations in liquid biopsy and FFPE breast tissue using qPCR (ECP 2024)
    The APIS ESR1 Mutations Kit showcased highly specific and sensitive detection of both the mutations present in the SensID ESR1 Reference Set 1% AF cfDNA and wildtype ESR1 from highly fragmented FFPE-derived DNA. Here, the kit’s LoD was affirmed at ≤1% MAF for cfDNA-based sample types and compatibility for detecting ESR1 mutations was demonstrated with both cfDNA and FFPEderived DNA samples.
    Liquid biopsy • Biopsy
    |
    ER (Estrogen receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation • ER mutation • ESR1 mutation
    |
    APIS ESR1 Mutations Kit
    7ms
    ESR1 mutations kit performance with SensID ESR1 reference set 1% AF. (ASCO 2024)
    The ESR1 Mutations Kit demonstrated highly sensitive and specific detection of the SensID ESR1 Reference Set 1% AF cfDNA, confirming the kit's LoD of ≤ 1% MAF with externally validated samples.
    ER (Estrogen receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    APIS ESR1 Mutations Kit
    1year
    Design and Development of the APIS ESR1 Mutations Kit to Detect Eleven Mutations Relevant to Acquired Endocrine Therapy Resistance (SABCS 2023)
    The ESR1 Mutations Kit demonstrated high sensitivity and performance as a qualitative qPCR assay to detect eleven ESR1 mutations. Mutations detected with the APIS ESR1 Mutations Kit
    ER (Estrogen receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    TP53 mutation • ER positive • KIT mutation • ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER L536Q • ER Y537C
    |
    APIS ESR1 Mutations Kit
    1year
    The Design and Development of the APIS ESR1 Mutations Kit to Detect Eleven Mutations Relevant to Acquired Endocrine Therapy Resistance. (AMP 2023)
    The APIS ESR1 Mutations Kit demonstrated high sensitivity and performance as a qualitative qPCR assay to detect 11 ESR1 mutations.
    ER (Estrogen receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    TP53 mutation • KIT mutation • ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER L536Q • ER Y537C
    |
    APIS ESR1 Mutations Kit
    1year
    Press release Biocartis group NV: Biocartis honors breast cancer awareness month with launch of breast cancer portfolio (Biocartis Press Release)
    "Biocartis Group NV...announces the launch of the new Breast Cancer Portfolio during the Breast Cancer Awareness month: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with APIS Assay Technologies (APIS), the APIS Breast Cancer Subtyping Kit and the APIS ESR1 Mutations Kit."
    Licensing / partnership • Launch
    |
    APIS Breast Cancer Subtyping Kit • APIS ESR1 Mutations Kit • Idylla™ PIK3CA-AKT1 Mutation Assay
    1year
    Press release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit (GlobeNewswire)
    "Biocartis Group NV...and APIS Assay Technologies Ltd...today announced the expansion of their partnership to include the commercialization of the APIS ESR1 Mutations Kit through Biocartis’ worldwide commercial network....'Together with the Idylla™ PIK3CA-AKT1 Mutation Assay and the APIS Breast Cancer Subtyping Kit we will be able to provide a comprehensive menu of products in the breast cancer domain to our customers.'"
    Licensing / partnership
    |
    APIS ESR1 Mutations Kit